CardioKinetix Inc. announced it has completed a $50 million financing led by Edwards Lifesciences Corp. with participation from other existing investors. This financing provides CardioKinetix with the capital necessary to complete the PARACHUTE IV randomized pivotal clinical trial of the Parachute ventricular partitioning device for the treatment of heart failure.

near-infrared spectroscopy, NIRS, heart attack, stroke, Infraredx, TVC

A study published in the Journal of the American College of Cardiology (JACC) shows intravascular near-infrared spectroscopy (NIRS) can identify lipid core-containing plaques, implicated in most heart attacks. The study shows the technology might be used as a means to predict the risk of future major adverse cardiac and cerebrovascular events (MACCE).

CardioCell LLC announced the treatment of its first patient in the University of Pennsylvania’s Phase IIa clinical trial for chronic heart failure (HF) of non-ischemic cardiomyopathy. 

Turner MedTech introduced ClearShield at RSNA, which is lead-free, eco-friendly, utilizes no lead and complies with European Union RoHS requirements. 

COR Medical Technologies (COR) introduces CORcare, a comprehensive instant outcome support system for rapid and accurate diagnosis, treatment, and follow-up management of patients with acute and chronic, common and rare diseases involving the cardiovascular system.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now